An Update on Autoinflammatory Diseases: Inflammasomopathies.

Cassandra R Harapas, Annemarie Steiner, Sophia Davidson, Seth L Masters

Journal: Current rheumatology reports 2019;20(7):40

PMID: 29846819

Abstract

PURPOSE OF REVIEW

Autoinflammatory diseases are driven by abnormal innate immune activation. In the case of inflammasomopathies, these are all attributable to activation of an inflammasome complex, nucleated by an innate immune sensor such as NLRP3. This review will focus on recent advances that have helped to elucidate the role of three other sensors (NLRP1, NLRC4 and pyrin) which can also cause inflammasomopathies.

RECENT FINDINGS

Mutations in pyrin (S242R or E244K) destroy an inhibitory 14-3-3 binding site and result in the newly characterised disease pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND). Moreover, a separate autoinflammatory disease driven by mevalonate kinase deficiency leads to defective RhoGTPase prenylation and subsequent loss of pyrin S242R phosphorylation, suggesting a shared mechanism of disease. Other inflammasomes such as NLRP1 and NLRC4 have had novel mutations described recently, which inform about the specific domains required for activation and autoinhibition. This review covers recent advances in the study of inflammasomopathies, focussing on gene discoveries that elucidate new pathogenic mechanisms.

Address: Inflammation division, The Walter and Eliza Hall Institute of Medical Research, Parkville, 3052, Australia.; Department of Medical Biology, University of Melbourne, Parkville, Victoria, 3010, Australia.; Inflammation division, The Walter and Eliza Hall Institute of Medical Research, Parkville, 3052, Australia. [email protected].; Inflammation division, The Walter and Eliza Hall Institute of Medical Research, Parkville, 3052, Australia. [email protected].; Department of Medical Biology, University of Melbourne, Parkville, Victoria, 3010, Australia. [email protected].

Link outs

Free resources

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.